Please enlighten us to why you think there won't be at least another 40 million share secondary driving the outstanding share count to close to 200 million outstanding shares.
The shelf registration is in place to dilute this pig and with continued losses and almost 200 million outstanding shares please explain how this will be anything more than a $2 stock by the end of 2013?
They are almost out of cash again and continue to spend more than they earn every quarter. This quarter will be another disappointment and EU approval means nothing when that country gives away free medicine.
They are over 2 years into this launch and they aren't even close to breakeven. Every quarter they do everything possible to spend more money than they bring in. Their only option is dilution since EU approval for generic cough medicine will be worthless when you compare it to the outstanding share count and the amount of money they will be spending on further indications which also have no potential.
Booming stock market and the Avanir bagholders have been here for 3 years just hoping to get back to breakeven.